β-Guanidinopropionic Acid: Properties, Uses & Research Guide

β-Guanidinopropionic acid is a naturally occurring creatine analog that competitively inhibits creatine uptake and serves as a powerful tool for investigating AMPK-mediated energy sensing and skeletal muscle metabolism in preclinical research.

Chemical Name

β-Guanidinopropionic acid (3-guanidinopropionic acid)

Molecular Formula

C₄H₉N₃O₂

Molecular Weight

131.13 g/mol

Mechanism of Action

Competitive inhibitor of the creatine transporter (CrT); depletes intracellular phosphocreatine stores and activates AMPK

Primary Research Use

Modeling low-energy states, AMPK activation, skeletal muscle metabolic adaptation studies

Physical Form

White to off-white crystalline powder

Solubility

Soluble in water

SKU

D137194

Chemical Identity and Physical Properties

β-Guanidinopropionic acid (β-GPA; also called 3-guanidinopropionic acid) is a low-molecular-weight guanidino compound with the molecular formula C₄H₉N₃O₂ and a molecular weight of approximately 131.13 g/mol. Structurally, it is the β-alanine analog of creatine, bearing a guanidinium group attached to the terminal carbon of a three-carbon chain with a free carboxylic acid at the other end.

The compound is isolated as a white to off-white crystalline solid that is freely soluble in water and sparingly soluble in most organic solvents. Stock solutions in phosphate-buffered saline or distilled water are commonly prepared at concentrations up to 100 mM for in vitro studies, while higher concentrations are employed for dietary supplementation in rodent models. Solutions should be stored at 4 °C when prepared fresh and protected from repeated freeze-thaw cycles to maintain chemical integrity.

β-GPA occurs naturally in trace amounts in certain plant species and in mammalian tissues, where it is produced as a minor metabolite of guanidino-amino acid pathways. Its structural similarity to creatine, differing only by the position of the guanidino group, underlies its competitive interaction with the creatine transport system.

Biochemical Mechanism: Creatine Transport Inhibition and AMPK Activation

The primary biochemical action of β-GPA is competitive inhibition of the creatine transporter (CrT, SLC6A8), the sodium-dependent membrane protein responsible for cellular creatine uptake. Because β-GPA competes with creatine for the same transporter, chronic exposure to β-GPA in vivo—typically delivered as a dietary supplement at 1–3% (w/w) in rodent chow—results in a substantial and sustained reduction of intracellular creatine and phosphocreatine (PCr) concentrations in skeletal muscle, heart, and brain.

Depletion of the phosphocreatine pool leads to a rise in the intracellular AMP-to-ATP ratio, which is sensed by AMP-activated protein kinase (AMPK). AMPK, the master regulator of cellular energy homeostasis, is allosterically activated by AMP binding and subsequently phosphorylated at Thr172 by upstream kinases LKB1 and CaMKKβ. Activated AMPK phosphorylates numerous downstream targets to restore energy balance, including stimulation of glucose uptake (via GLUT4 translocation), enhancement of fatty acid oxidation, inhibition of anabolic processes, and promotion of mitochondrial biogenesis through PGC-1α.

This mechanism makes β-GPA a pharmacological tool for creating a controlled low-energy cellular environment that mimics aspects of exercise or nutrient deprivation, without requiring physical intervention in animal subjects. Importantly, the depletion is reversible upon withdrawal of β-GPA treatment.

Research Applications and Experimental Models

β-GPA is widely employed across several research disciplines owing to its reliable and reproducible ability to modulate intracellular energy charge:

• Skeletal Muscle Metabolism: Dietary β-GPA supplementation in rodents is a well-established model for studying adaptations to chronic energy deficit in muscle, including fiber-type transitions, mitochondrial remodeling, and metabolic flexibility.
• AMPK Pathway Research: β-GPA is used as a positive control or complementary tool alongside pharmacological AMPK activators (e.g., AICAR, metformin) to validate pathway engagement in cell culture and in vivo experiments.
• Cardiac Energy Metabolism: PCr depletion by β-GPA has been used to explore cardiac energetics and the heart's response to reduced phosphagen buffering capacity.
• Neurological Studies: Given that CrT is expressed in the brain, β-GPA has been employed in models examining the role of creatine-phosphocreatine shuttling in neuronal function and neuroprotection.
• Obesity and Insulin Resistance: Because AMPK activation improves insulin sensitivity and lipid metabolism, β-GPA-treated rodents serve as a model to probe AMPK-dependent anti-diabetic pathways.

For in vitro use, β-GPA is applied to cultured myotubes, cardiomyocytes, or neuronal cells at millimolar concentrations to acutely or chronically suppress creatine availability, followed by measurement of AMPK phosphorylation, mitochondrial markers, or metabolic flux.

Handling, Storage, and Purity Considerations

For optimal experimental outcomes, researchers should adhere to the following best practices when working with β-GPA (Aladdin SKU D137194):

Storage: Store the dry solid at room temperature (15–25 °C) in a tightly sealed container, protected from moisture and direct light. Aqueous solutions should be stored at 4 °C and used within two weeks, or aliquoted and stored at −20 °C for longer-term use.

Purity and Grade: Research-grade β-GPA should be characterized by HPLC purity ≥98% to ensure reproducibility of pharmacological effects, particularly when used for quantitative AMPK assays or metabolic flux measurements. Researchers are advised to confirm purity certification with the accompanying Certificate of Analysis (CoA).

Safety: β-GPA is not classified as a highly hazardous substance under standard laboratory safety guidelines; however, standard laboratory precautions apply: avoid inhalation of dust, use appropriate PPE (gloves, lab coat, eye protection), and consult the Safety Data Sheet (SDS) prior to use. Chronic high-dose oral intake should be handled under appropriate institutional biosafety protocols in animal studies.

Preparation Tips: Weigh the compound under low-humidity conditions. When preparing rodent chow admixtures, ensure thorough mixing to achieve homogeneous distribution. For cell culture work, filter-sterilize aqueous stock solutions through a 0.22 µm membrane before use.

Comparison with Related Creatine Pathway Reagents

Understanding where β-GPA fits among related research tools helps researchers select the most appropriate reagent for their experimental design:

Reagent	Mechanism	Primary Effect	Common Model
β-Guanidinopropionic acid (β-GPA)	CrT competitive inhibitor	PCr depletion → AMPK activation	Rodent dietary model; cell culture
Creatine	CrT substrate; phosphorylated by CK	Increases PCr buffering capacity	Ergogenic and neuroprotection studies
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide)	Direct AMPK activator (AMP mimetic)	AMPK activation independent of PCr	Cell culture; in vivo injection
Metformin	Complex I inhibitor → raises AMP/ATP	AMPK activation; metabolic effects	Diabetes models; cell culture

Unlike direct AMPK activators such as AICAR, β-GPA acts upstream by depleting the phosphocreatine energy buffer, providing a physiologically relevant model of energy stress that mimics prolonged exercise or energetic insufficiency. This upstream mechanism also makes β-GPA useful for studies where the researcher wishes to interrogate the creatine-phosphocreatine system specifically, rather than activate AMPK through a non-physiological route.

Frequently asked questions

What is the recommended concentration of β-GPA for rodent dietary depletion studies?

β-GPA is typically incorporated into rodent chow at 1–3% (w/w) for chronic dietary supplementation models lasting 3–8 weeks. This regimen reliably reduces skeletal muscle phosphocreatine content and activates AMPK. Researchers should verify the specific concentration and duration with published literature relevant to their tissue and endpoint of interest.

Can β-GPA be used to activate AMPK in cell culture experiments?

Yes, β-GPA can be applied to cultured cells, including myotubes and cardiomyocytes, at millimolar concentrations (typically 1–20 mM) to inhibit creatine uptake and reduce intracellular phosphocreatine, thereby activating AMPK. Results may vary depending on cell type, incubation time, and baseline creatine transporter expression levels, so optimization is recommended.

How does β-GPA differ from AICAR as an AMPK activator?

AICAR is a cell-permeable AMP analog that directly activates AMPK by mimicking the allosteric effect of AMP. β-GPA, by contrast, acts upstream by depleting phosphocreatine stores via creatine transporter inhibition, causing an indirect rise in the AMP/ATP ratio that subsequently activates AMPK. β-GPA thus provides a more physiologically relevant energy-stress model, while AICAR offers a more direct and acute activation mechanism.

Is β-GPA treatment reversible?

Yes, the phosphocreatine depletion induced by β-GPA is reversible. Upon withdrawal of dietary or in vitro β-GPA supplementation, intracellular creatine and phosphocreatine levels gradually recover as the creatine transporter resumes normal creatine uptake. This reversibility is an important advantage when designing washout or recovery experiments.

What purity grade of β-GPA is appropriate for quantitative biochemical assays?

For quantitative assays such as AMPK phosphorylation measurements, metabolic flux analysis, or dose-response studies, research-grade β-GPA with HPLC purity ≥98% is recommended. Always consult the Certificate of Analysis (CoA) provided with each lot to confirm purity and identity before use in critical experiments.

References

1. Shoubridge EA, Challiss RA, Hayes DJ, Radda GK. Biochemical adaptation in the skeletal muscle of rats depleted of creatine with the substrate analogue beta-guanidinopropionic acid. Biochem J. 1985.
2. Bergeron R, Russell RR 3rd, Young LH, et al. Effect of AMPK activation by contraction on muscle glucose transport. Am J Physiol. 1999.
3. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011.
4. Reznick RM, Shulman GI. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol. 2006.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.